Correspondence 0001213900-22-070586 from Clearmind Medicine Inc. (CMND)
Clearmind Medicine Inc.
Date: Nov. 9, 2022 · CIK: 0001892500 · Accession: 0001213900-22-070586
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-265900
Letter
RE: Clearmind Medicine, Inc. (CIK: 0001892500)
November 9, 2022
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Registration Statement on Form F-1 (the “Registration Statement”)
Reg. No. 333-265900
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), Aegis Capital Corp. hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 4:30 p.m. Eastern Time, on November 10, 2022, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that we will distribute as many electronic copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution.
By: AEGIS CAPITAL CORP.
By: /s/ Griffin Cassagne
Name: Griffin Cassagne
Title: Executive Vice President
Show Raw Text
CORRESP
1
filename1.htm
November 9, 2022
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
RE:
Clearmind Medicine, Inc. (CIK: 0001892500)
Registration Statement on Form F-1 (the “Registration Statement”)
Reg. No. 333-265900
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities
and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), Aegis Capital Corp.
hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at
4:30 p.m. Eastern Time, on November 10, 2022, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that we
will distribute as many electronic copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate
distribution.
By:
AEGIS CAPITAL CORP.
By:
/s/ Griffin Cassagne
Name: Griffin Cassagne
Title: Executive Vice President